Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments
UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co....
Roche Gains FDA 510(k) Clearance for Roche Digital Pathology Dx with VENTANA DP 600
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced an additional 510(k) clearance from the...
TCMTech Files for IPO on Hong Kong Stock Exchange, Showcasing TCM AI Leadership
China-based TCMTech Inc., recognized as the largest artificial intelligence (AI) empowered traditional Chinese medicine (TCM)...
Verdiva Bio Launches with USD 411 Million Series A Financing for Biopharma Development
UK-based Verdiva Bio Limited has announced its launch as a clinical-stage biopharma company, backed by...
ImmVira Partners with Merz Aesthetics to Develop Anti-Wrinkle Exosome Products
Shenzhen-based ImmVira’s exosomes-focused subsidiary has struck a partnership with US leading firm Merz Aesthetics. The...
SciWind Bio and Verdiva Bio Partner on Global Development of Obesity Therapies
On January 10, SciWind Bio announced a global development and commercialization license and collaboration agreement...
MediLink and Zai Lab Collaborate on LRRC15-Targeted ADC Drug ZL-6201
Chinese biotechs MediLink Therapeutics (Suzhou) Co., Ltd and Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688)...
Bayer’s Elinzanetant Meets All Primary Endpoints in Phase III OASIS 4 Study
Germany-based Bayer AG (ETR: BAYN) has announced that the Phase III OASIS 4 study for...
Inmagene Biopharmaceuticals Posts Positive Results for IMG-007 in Atopic Dermatitis
Inmagene Biopharmaceuticals, a Sino-US biotech that recently merged with US-based Ikena Oncology, Inc. (NASDAQ: IKNA),...
BrainAurora Medical Technology IPOs on Hong Kong Stock Exchange
Zhejiang-based BrainAurora Medical Technology Limited (HKG: 6681), the first company in China to combine neuroscience...
NMPA Releases 89th Batch of Reference Drugs for GQCE Work
The National Medical Products Administration (NMPA) has released the 89th batch of reference drugs for...
China’s NHC Aims for Over 90% Child-Friendly Hospitals by 2030
The Department of Maternal and Child Health Care of the National Healthcare Commission (NHC) has...
Stryker to Acquire Inari Medical for USD 4.9 Billion to Boost VTE Pipeline
US-based Stryker (NYSE: SYK) has reached a definitive acquisition agreement with compatriot firm Inari Medical,...
GSK Launches Cabotegravir Injection in China for HIV Pre-Exposure Prophylaxis
UK-based GlaxoSmithKline (GSK; NYSE: GSK) has announced the official commercial launch of its cabotegravir injection...
Insilico Medicine Raises USD 100 Million in Financing Round Led by Pudong and Hong Kong
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has reportedly raised USD 100 million in...
Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS
Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS...
NHSA Revises 2024 NRDL Drug Information Based on Public Feedback
China’s National Healthcare Security Administration (NHSA) has announced revisions to the information about certain drugs...
Eli Lilly China’s Neuroscience VP Jiang Yifei Departs for New Opportunities
Jiang Yifei, the current vice president of Eli Lilly (NYSE: LLY) China’s neuroscience division, has...
Fourier Intelligence Secures USD 109 Million in Series E Funding for Robotics Innovation
China-based Shanghai Fourier Intelligence Co., Ltd, a leading developer of exoskeleton robotic products for rehabilitation...
Astellas’ Padcev and Keytruda Combo Cleared by NMPA for Urothelial Cancer
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced marketing clearance by China’s National Medical Products...